奥硝唑唾液浓度与血药浓度的相关性分析
x

请在关注微信后,向客服人员索取文件

篇名: 奥硝唑唾液浓度与血药浓度的相关性分析
TITLE:
摘要: 目的:探讨健康受试者奥硝唑(ONZ)唾液浓度与血药浓度的相关性,为临床治疗药物监测提供参考。方法:选择健康受试者24名,口服ONZ胶囊1.00 g后,分别于给药后的0.25、0.5、1.5、5.5、10.5、24.5、43.5 h采集静脉血和唾液,采用高效液相色谱法分别测定ONZ在血浆和唾液中的质量浓度,比较两者的相关性。结果:24名健康受试者血浆和唾液中ONZ质量浓度峰值均出现在给药后1.5 h,其峰值分别为(0.96±0.15)和(0.93±0.15)μg/ml;各时间点ONZ唾液浓度虽低于血药浓度,但差异均无统计学意义(P>0.05);唾液浓度与血药浓度的回归方程为c唾=1.176 5c血-0.199 4(r=0.990 1),其平均质量浓度的比值(S/P)为(0.91±0.06),两者呈正相关(r为0.632~0.970,P<0.05)。结论:ONZ在健康受试者唾液中的质量浓度与血药浓度显著正相关,可应用唾液进行治疗药物监测。
ABSTRACT: OBJECTIVE: To explore the correlation between ornidazole (ONZ) salivary concentration and plasma concentrations in healthy subjects, and to provide reference for clinical therapeutic drug monitoring. METHODS: 24 healthy volunteers were selected. After oral administration of ONZ capsules 1.00 g, their venous blood and saliva were collected at 0.25, 0.5, 1.5, 5.5, 10.5, 24.5 and 43.5 h after medication. HPLC method was used to determine the plasma and salivary concentrations of ONZ. The correlation between the two was analyzed. RESULTS: The peak values of plasma and salivary ONZ concentrations appeared immediately at 1.5 h after administration and the peak values were (0.96±0.15) μg/ml and (0.93±0.15) μg/ml; salivary concentration of ONZ was lower than plasma concentration at each time points, but there was no statistical significance (P>0.05); the regression equation of salivary ONZ concentration and plasma concentration was csaliva=1.176 5cplasma-0.199 4(r=0.990 1). The ratio of salivary concentration and plasma concentration of ONZ (S/P) was (0.91±0.06), showing positive correlation (r=0.632-0.970,P<0.05). CONCLUSIONS: The salivary ONZ concentration is significantly correlated with plasma concentration in healthy people, so saliva can be used for therapeutic drug monitoring.
期刊: 2016年第27卷第29期
作者: 谢燕贤,刘杰,符方方,黄伟芳
AUTHORS: XIE Yanxian,LIU Jie,FU Fangfang,HUANG Weifang
关键字: 奥硝唑;高效液相色谱法;唾液;血浆;药物浓度
KEYWORDS: Ornidazole; HPLC; Saliva; Plasma; Drug concentration
阅读数: 260 次
本月下载数: 4 次

* 注:未经本站明确许可,任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作!